Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06585865 · ClinicalTrials.gov registry record · NA
Strength Training and Resveratrol
A NA study of Sarcopenia and Anabolic Resistance, sponsored by Texas Tech University.
- Recruiting
- Registry status
- NA
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06585865: Recruiting NA study of Sarcopenia and Anabolic Resistance, sponsored by Texas Tech University.
NCT06585865 is a NA study of Sarcopenia and Anabolic Resistance that is actively recruiting participants, run by Texas Tech University. The registered enrollment target is 36 participants, below the 80-participant average among 41 other Sarcopenia trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06585865, a NA study of Sarcopenia and Anabolic Resistance, is actively recruiting participants, sponsored by Texas Tech University.
- RECRUITING
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles) and their cargo might help explain those responses. The investigators will also examine whether resveratrol supplementation improves blood vessel function and cognitive function (brain health) in response to strength training.
Primary Outcome
Circulating extracellular vesicles will be isolated from plasma and their microRNA cargo will be sequenced.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- BEHAVIORAL Resistance training
- DIETARY_SUPPLEMENT Resveratrol 500 mg oral once daily.
Study Locations (1)
Texas
- Department of Kinesiology & Sport Management, Texas Tech University - Lubbock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-06-13 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06585865 shows while recruiting
NCT06585865 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 80-participant average among 41 other Sarcopenia trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with Sarcopenia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06585865 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06585865 about?
NCT06585865 is a clinical study titled "Strength Training and Resveratrol". The main goal of this study is to find out if supplementing with resveratrol improves skeletal muscle adaptations to strengthening exercise (resistance training or strength training) in adults age 60+, and to determine whether circulating vehicles of inter-organ communication (extracellular vesicles...
What is the current status of trial NCT06585865?
This trial is currently recruiting. It is a NA study. The enrollment target is 36 participants. The study started on 2025-06-13. Estimated completion is 2026-08.
What conditions does trial NCT06585865 study?
This clinical trial studies the following conditions: Sarcopenia, Anabolic Resistance.
What interventions are being tested in trial NCT06585865?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Resistance training (BEHAVIORAL), Resveratrol 500 mg oral once daily. (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06585865?
This trial is sponsored by Texas Tech University, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06585865 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06585865's enrollment target sits among peer trials
36 29th of 41 higher than 13 of 41 other Sarcopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients
RECRUITING · NA
-
Effects of Whole-body Electrical Muscle Stimulation Exercise on Spinal Motoneuronal Activation in Older Adults
RECRUITING · NA
-
Project Gnosis: the Neurophysical and Psychosocial Health Outcomes of Tai Chi for Older Adults with Cognitive Concerns or Mild Cognitive Impairment
RECRUITING · NA
-
Multidimensional Predictive Modeling to Understand Mechanisms of Exercise Response Heterogeneity in Older Adults (M3AX)
RECRUITING · NA
-
C-Protein in Fatigue and Aging
RECRUITING · NA
-
Adverse Outcomes and Mortality in Liver Transplant
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI